Ipsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a licence to develop and market a drug for the rare disease fibrodysplasia ossifican
Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA for adjuvant use after surgery in early-stage,
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.